KALA PHARMACEUTICALS INC's ticker is KALA and the CUSIP is 483119103. A total of 77 filers reported holding KALA PHARMACEUTICALS INC in Q1 2019. The put-call ratio across all filers is - and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2020 | $37,000 | -9.8% | 5,500 | 0.0% | 0.01% | -30.8% |
| Q3 2020 | $41,000 | -29.3% | 5,500 | 0.0% | 0.01% | -40.9% |
| Q2 2020 | $58,000 | +20.8% | 5,500 | 0.0% | 0.02% | 0.0% |
| Q1 2020 | $48,000 | +140.0% | 5,500 | 0.0% | 0.02% | +175.0% |
| Q4 2019 | $20,000 | -4.8% | 5,500 | 0.0% | 0.01% | -11.1% |
| Q3 2019 | $21,000 | -41.7% | 5,500 | 0.0% | 0.01% | -43.8% |
| Q2 2019 | $36,000 | -21.7% | 5,500 | 0.0% | 0.02% | -33.3% |
| Q1 2019 | $46,000 | – | 5,500 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| CAXTON CORP | 771,790 | $5,788,000 | 5.46% |
| RA Capital Management | 10,874,613 | $81,560,000 | 1.49% |
| Mesirow Financial Investment Management, Inc. | 36,445 | $273,000 | 1.17% |
| Samsara BioCapital, LLC | 451,162 | $3,384,000 | 0.94% |
| Parkman Healthcare Partners LLC | 310,053 | $2,325,000 | 0.62% |
| Orbimed Advisors | 5,465,030 | $40,988,000 | 0.52% |
| Eventide Asset Management | 3,450,000 | $25,875,000 | 0.51% |
| Vivo Capital, LLC | 786,883 | $5,902,000 | 0.34% |
| Ikarian Capital, LLC | 451,531 | $3,387,000 | 0.24% |
| Matisse Capital | 50,300 | $377,000 | 0.15% |